Get the Stockscreener App
60.16
1.60%
-0.98
Biomarin Pharmaceutical Inc stock is traded at $60.16, with a volume of 1.21M.
It is down -1.60% in the last 24 hours and up +8.40% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$61.14
Open:
$61.24
24h Volume:
1.21M
Relative Volume:
0.42
Market Cap:
$11.56B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
22.36
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
+16.14%
1M Performance:
+8.40%
6M Performance:
+10.00%
1Y Performance:
-9.71%
1-Day Range:
$59.81
$61.24
1-Week Range:
$51.50
$63.89
52-Week Range:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
60.16 | 11.75B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
BioMarin names new chief accounting officer - MSN
Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED) - Benzinga
Silver Tops $70, Novo Nordisk Soars 9% On Obesity Pill ApprovalBullish (NYSE:BLSH), BioMarin Pharmaceutical (NASDAQ:BMRN) - Benzinga
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion - New Jersey Business Magazine
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Finviz
What's Going On With BioMarin Stock On Tuesday? - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 3.9% Higher on Analyst Upgrade - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $100.00 Price Target at Truist Financial - MarketBeat
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition - Finviz
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Narrow-Moat BioMarin's $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio - Morningstar
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Disc Medicine (IRON) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail
BioMarin (BMRN) Stock News Today: Amicus Acquisition Fallout, BMN 349 Cut, and Fresh Wall Street Price Targets (Dec. 22, 2025) - ts2.tech
American biotech company BioMarin acquires Amicus Therapeutics for $4.8 billion - AKM.RU
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN) - Seeking Alpha
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B - sharewise.com
7 Most Promising Gene Editing Stocks According to Analysts - Insider Monkey
BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push - Pharmaceutical Technology
BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement - Fierce Biotech
BioMarin stock price target raised to $100 from $80 at Truist Securities - Investing.com UK
BioMarin stock price target raised to $100 from $80 at Truist Securities By Investing.com - Investing.com Australia
BioMarin drops development of liver, lung disease asset - Seeking Alpha
Truist Securities Lifts BioMarin Pharmaceutical Price Target to $100 From $80, Maintains Buy Rating - marketscreener.com
BioMarin ends development of BMN 349 for AATD liver disease - Investing.com
BioMarin Ends Development of BMN 349 AATD Therapy - TipRanks
BioMarin stock price target raised to $60 from $55 at H.C. Wainwright By Investing.com - Investing.com South Africa
BioMarin ends development of BMN 349 for AATD liver disease By Investing.com - Investing.com UK
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $60.00 Price Target at HC Wainwright - MarketBeat
BioMarin stock price target raised to $60 from $55 at H.C. Wainwright - Investing.com
HC Wainwright & Co. Maintains BioMarin Pharmaceutical (BMRN) Neutral Recommendation - Nasdaq
BioMarin ends year with $4.8bn play for Amicus - pharmaphorum
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
BioMarin Reaches $4.8 Billion Definitive Agreement to Acquire Amicus Therapeutics - RamaOnHealthcare
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025 - ts2.tech
BioMarin Pharmaceutical (BMRN) Stock Price, Quote, News & History - Benzinga
Rivian, Sandisk, And Moderna Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?Affirm Holdings (NASDAQ:AFRM), BioMarin Pharmaceutical (NASDAQ:BMRN), Carnival (NYSE:CCL), Lumentum Holdi - Benzinga
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025) - ts2.tech
Why BioMarin Pharmaceutical Inc. stock is trending among retail tradersEarnings Risk Summary & Risk Adjusted Buy/Sell Alerts - Улправда
Biotechnology Stocks Week Ahead (Dec. 22–26, 2025): BioMarin–Amicus Deal, Cytokinetics FDA Win, IPO Filings, and Drug-Price Policy Risks - ts2.tech
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025) - ts2.tech
Key deals this week: Trump Media & Technology, Howard Hughes, BioMarin Pharmaceutical and more - Seeking Alpha
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare disease company with a presence in Philadelphia - MSN
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025) - ts2.tech
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion - ts2.tech
After shakeup under new CEO, drugmaker BioMarin turns its cash on a big deal - The Business Journals
BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus - Finviz
10 Firms in the Limelight - Insider Monkey
BioMarin Pharmaceutical Inc. $BMRN Stake Cut by Assenagon Asset Management S.A. - MarketBeat
BioMarin to acquire Amicus Therapeutics for $4.8 billion By Investing.com - Investing.com South Africa
Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open - ts2.tech
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):